ROSATOM, new radium, actinium and thorium separation technology

On 19 February 2025, ROSATOM scientists at the Research Institute of Nuclear Reactors (RIAR) patented a new technology for the separation of radium, actinium and thorium. Under an agreement with the Russian Ministry of Industry and Trade, this pioneering technology was developed in Dimitrovgrad, Russia. The technology enables the production of actinium-225, a highly valuable isotope used in nuclear medicine and cancer therapy. The process ensures high quality production while meeting stringent control standards. The actinium-225 isotope is considered one of the most promising alpha emitters for medical applications. This breakthrough technology has been developed to advance nuclear medicine, particularly targeted cancer therapy. Actinium-225 has unique properties that make it a powerful tool in the fight against cancer, providing precision in radiation therapy with minimal damage to healthy tissue. The patent strengthens ROSATOM’s position in nuclear science and contributes to global progress in the development of medical isotopes.